Locally Advanced Malignant Neoplasm Clinical Trial
Official title:
Olaparib Dose Escalation in Combination With High Dose Radiotherapy to the Breast Andregional Lymph Nodes in Patients With Breast Cancer
Verified date | August 2021 |
Source | The Netherlands Cancer Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The majority of breast cancer patients receive radiotherapy as part of their treatment. Radiotherapy improves both locoregional control and overall survival. In most patients with breast cancer the locoregional recurrence rate (LRR) is low, however still high LRRs are found in certain patient groups, especially in locally advanced, inflammatory and triple negative breast cancer. Olaparib is a potent PARP inhibitor developed as an anti-cancer drug for homologous recombination (HR) defected tumors and as a dose intensifier for chemo- and radiotherapy. The combination of olaparib and radiotherapy is expected to improve locoregional control and thereby overall survival in both breast cancer patients with a high probability of locoregional recurrence and patients with HR deficient tumors. However, this combination treatment has never been tested in humans before. The purpose of this study is to determine the safety and tolerability of radiotherapy to the breast and regional lymph nodes with concurrent olaparib.
Status | Completed |
Enrollment | 7 |
Est. completion date | August 2020 |
Est. primary completion date | September 2019 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - =18 years of age - Histological proven breast cancer or local recurrence of breast cancer which is inoperable or/and metastatic, including inflammatory breast cancer - No participation in trial with neoadjuvant systemic treatment, except for previous contralateral breast cancer - Tumor in breast accessible for biopsy - WHO performance 0-2 - Life expectancy of at least 6 months - Adequate hematological, renal and hepatic functions - Hemoglobin 6.2 mmol/l - Leucocytes 3.0 x 10E9/l - Absolute neutrophil count 1.5x10E9/l - Platelet count 100 x 10E9/l - Total bilirubin = 1.5 x ULN - ASAT/ALAT = 2.5 x ULN; or in the presence of liver metastases = 5 x ULN - Creatinine clearance 50 ml/min; measured or calculated - Evidence of non-childbearing status for women of childbearing potential: negative urine or serum pregnancy test within 21 days of study treatment. Non-childbearing potential or postmenopausal is defined as: - Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments - LH and FSH levels in post menopausal range for women under 50 years of age - Radiation-induced oophorectomy with last menses > 1 year ago - Chemotherapy-induced menopause with > 1 year interval since last menses - Surgical sterilisation (bilateral oophorectomy or hysterectomy) - Patients of reproductive potential must agree to practice two effective medically approved contraceptive method during the trial and 3 months afterwards - Signed written informed consent Exclusion Criteria: - Anti-cancer therapy including chemotherapy, radiotherapy, endocrine therapy, immunotherapy or use of other investigational agents within 3 weeks prior to start of therapy (or a longer period depending on the defined characteristics of the agents used e.g. 6 weeks for mitomycin ornitrosourea). Patient may continue the use of tamoxifen, aromatase inhibitor and LHRH agonists for cancer; bisphosphonates for bone disease and corticosteroids. The use of denosumab for bone disease is not allowed. - Major surgery within two weeks of starting study treatment. - Participation in other trial with investigational drug or treatment modality - Patients with symptomatic uncontrolled brain metastases. A scan to confirm the absence of brain metastases is not required. - Prior ipsilateral radiotherapy to the chest or breast. - Blood transfusion in the four weeks prior to study entry - Persistent toxicities (CTC = grade 2) with the exception of alopecia, caused by previous cancer therapy - QT-interval > 470 msec - Significant cardiovascular disease as defined by - History of congestive heart failure defined as NYHA class III - History of unstable angina pectoris or myocardial infarction up to 3 months prior to trial entry; - Presence of severe valvular heart disease - Presence of a ventricular arrhythmia requiring treatment; - Uncontrolled hypertension - Patients considered a poor medical risk due to: - non-malignant systemic disease - active, uncontrolled infection requiring parenteral antibiotics - a serious, uncontrolled medical disorder; examples include, but are not limited to: - uncontrolled major seizure disorder - unstable spinal cord compression - superior vena cava syndrome - extensive bilateral lung disease on HRCT scan - any psychiatric disorder that prohibits obtaining informed consent. - Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule. - Patients who are known to be serologically positive for human immunodeficiency virus (HIV) and are receiving antiviral therapy. - Patients with known active hepatic disease (i.e. Hepatitis B or C) - Patients with myelodysplastic syndrome/acute myeloid leukaemia or features suggestive of MDS/AML on peripheral blood smear. - Gastrointestinal disorders that may interfere with absorption of the study drug or patients who are not able to take oral medication - Concomitant medications: - Any previous treatment with a PARP inhibitor, including Olaparib - Patients receiving the following classes of inhibitors of CYP3A4 (see Section 6.4.2 for guidelines and wash out periods) - Azole antifungals - Macrolide antibiotics - Protease inhibitors - Patients with a known hypersensitivity to olaparib or any of the excipients of the product - Breast-feeding women |
Country | Name | City | State |
---|---|---|---|
Netherlands | The Netherlands Cancer Institute | Amsterdam |
Lead Sponsor | Collaborator |
---|---|
The Netherlands Cancer Institute |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The incidence of dose limiting toxicities. | 1 year | ||
Secondary | Acute toxicity | severity, duration and relation with treatment of all adverse events according to CTCAE version 4.03 occurring from start of treatment until 3 months after end of treatment | 3 months after treatment | |
Secondary | Late toxicity | severity, duration and relation with treatment of all adverse events that are possibly, probably or definitely related to the combination treatment according to CTCAE version 4.03 | 3 months until 2 years after end of treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03671226 -
Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their Caregivers Who Are Seen in the Outpatient Supportive/Palliative Care Center
|
N/A | |
Completed |
NCT01973673 -
Healthy Bones Study
|
N/A | |
Completed |
NCT01876927 -
Pre-Operative Or Peri-Operative Dox Regimen In Patients With Locally Advanced Resectable Gastric Cancer
|
Phase 2 | |
Terminated |
NCT03295942 -
A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors
|
Phase 1 | |
Completed |
NCT03238027 -
A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04260802 -
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
|
Phase 1/Phase 2 | |
Completed |
NCT02823652 -
Pre-Test Genetic Education and Remote Genetic Counseling in Communicating Tumor Profiling Results to Patients With Advanced Cancer
|
N/A | |
Recruiting |
NCT01871363 -
Phase II Study of Preoperative IMRT Combined With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer
|
Phase 2 | |
Completed |
NCT01847001 -
Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
|
Phase 2 | |
Terminated |
NCT03170115 -
Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer
|
Phase 2 | |
Recruiting |
NCT04749108 -
Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma
|
Phase 2/Phase 3 | |
Terminated |
NCT01836432 -
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
|
Phase 3 | |
Recruiting |
NCT01675999 -
Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer
|
Phase 2 | |
Completed |
NCT01325558 -
A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT01333709 -
Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma
|
Phase 2 | |
Withdrawn |
NCT03849742 -
Ride to Care - Quality of Life With Transportation for RT
|
N/A | |
Active, not recruiting |
NCT03856060 -
Videos and Questionnaires in Assessing Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits
|
N/A | |
Completed |
NCT04186884 -
Caregiver Burden, Quality of Life, and Symptom Distress at Different Palliative Cancer Care Settings
|
||
Recruiting |
NCT04112836 -
Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer
|
||
Not yet recruiting |
NCT03051152 -
D1 Versus D2 Lymphadenectomy in High Risk Elderly With Gastric Adenocarcinoma
|
N/A |